Launch of the Personalized Medicine Partnership for Cancer
- Home
- Press Room
- Latest News
- Launch of the Personalized Medicine Partnership for Cancer
» Share this page
Friday February 15, 2013
The Government of Québec announced today an investment in the Personalized Medicine Partnership for Cancer (PMPC). The PMPC will be under the leadership of Caprion Proteome Inc., a Montreal-based biotech company specializing in the discovery and development of protein-based diagnostic biomarkers.
Génome Québec congratulates Martin LeBlanc, President and Chief Executive Officer of Caprion Proteomics, who is the head of this public-private partnership with a total value of $ 21.1 million.
For more information, click here.